Living with Lupus: Breaking the Silence
Published in eyeforpharma July 2017 by Mariel Metcalfe
Lupus is an almost invisible disease, yet can have considerable impact on patients’ quality of life, but there is much that pharma can do to help.
Research Partnership has published a new Living with Lupus (SLE) market report for 2017
SLE is a progressive and debilitating disease which affects 5 million people worldwide. Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US, France and Germany. The report consists of 30-minute online interviews with 262 SLE patients (including those with lupus nephritis); fifteen follow-up qualitative interviews were also conducted. All patients were required to be on an immunosuppressant or biologic therapy; the final sample includes 15-20% on biologics.
Lupus study reveals Benlysta favoured as future biologic of choice
With Benlysta’s approval and further drugs in the pipeline, the market for SLE is expected to grow substantially over the next 10 years, making this fast-changing disease area a key market to watch.
With Benlysta’s approval and further drugs in the pipeline, the market for SLE is expected to grow substantially over the next 10 years, making this fast-changing disease area a key market to watch. Wave one of Therapy Watch Lupus (SLE) provided us with a snapshot of the SLE market, identifying the current market trends which will most likely impact future brand strategy.
The study revealed that, despite its focus on SLE, Benlysta’s uptake has been more gradual than many predicted since its approval and it currently holds a similar proportion of the market as Rituximab/MabThera, which is prescribed off-label.
Therapy Watch launches Lupus, a new patient tracking study
Recently, we’ve seen a change in the treatment landscape for lupus with biologics increasingly being used to control the disease. In light of this, and because of client demand, we are expanding our portfolio of autoimmune products to now include Therapy Watch Lupus.
To keep in step with the market dynamics as they happen, Therapy Watch Lupus will be a quarterly study amongst 280 rheumatologists across France, Germany, Italy, Brazil, Canada and the US, submitting information on 2,000+ patients each wave.